Clinical Trials Logo

Transarterial Chemoembolization clinical trials

View clinical trials related to Transarterial Chemoembolization.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05025592 Not yet recruiting - HCC Clinical Trials

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

Start date: September 10, 2021
Phase:
Study type: Observational

explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1 antibody or not for unresected hepatocellular carcinoma (uHCC)

NCT ID: NCT04834674 Not yet recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above. Its incidence accounts for about 15%-20% of primary liver malignancies, showing a gradually increasing trend. Surgical resection is currently the main method for the treatment of ICC. However, most (60% -70%) patients are diagnosed at the advanced stage. Gemcitabine plus cisplatin is the standard first-line incurable resection recommended in international and domestic guidelines. There is not a standard second-line treatment that has progressed after standard first-line chemotherapy. The clinical benefits of immune therapies for HCC are emerging. Early clinical data already show the safety of immune checkpoint inhibition. This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC that has progressed after standard first-line chemotherapy. Patients who were aged 18 to 80 years with a histological or cytological diagnosis of ICC,locally advanced or multiple liver metastases, including progression after gemcitabine chemotherapy, will be enrolled in this trial.

NCT ID: NCT04597970 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC

OXRI
Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

Purpose:explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)